NT5E and non-small cell lung carcinoma: For the treatment of stage III unresectable NSCLC, however, a multi-combinatorial approach with additive targeting of CD73 to the established PACIFIC regimen (concurrent chemo-radiotherapy with anti-PD-L1 consolidation) is evaluated in clinical trials (COAST and PACIFIC-9).